Aspirin and other antiplatelet agents are widely used in patients with chronic kidney disease. However, their use is often based on data obtained in patients with normal renal function. A recent Cochrane Collaboration systematic review analysed the benefits and risks of these agents in patients with chronic kidney disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Palmer, S. C. et al. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD008834. http://dx.doi.org/10.1002/14651858.CD008834.pub2.
Palmer, S. C. et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am. J. Kidney Dis. 61, 112–122 (2013).
Kahn, M. R., Robbins, M. J., Kim, M. C. & Fuster, V. Management of cardiovascular disease in patients with kidney disease. Nat. Rev. Cardiol. http://dx.doi.org/10.1038/nrcardio.2013.15.
Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238–248 (2005).
Wright, R. S. et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann. Intern. Med. 137, 563–570 (2002).
Shroff, G. R., Li, S. & Herzog, C. A. Survival of US dialysis patients after acute myocardial infarction: is it finally getting better in the modern treatment era? [abstract]. Presented at the 2012 American Heart Association Scientific Sessions.
U. S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. National Institutes of Health, Bethesda, 2012.
Hiremath, S., Holden, R. M., Fergusson, D. & Zimmerman, D. L. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin. J. Am. Soc. Nephrol. 4, 1347–1355 (2009).
Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138, 1093–1100 (2010).
Krueger, T., Westenfeld, R., Ketteler, M., Schurgers, L. J. & Floege, J. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification? Kidney Int. 76, 18–22 (2009).
Acknowledgements
The statistical advice of Nicole Heussen and Ralf-Dieter Hilgers, Institute of Medical Statistics, RWTH University of Aachen, Germany, and of Friedo Dekker, Department of Clinical Epidemiology, Leiden University Medical Centre, The Netherlands, is gratefully acknowledged.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Floege, J., Schlieper, G. How effective and safe are antiplatelet agents in CKD?. Nat Rev Nephrol 9, 314–316 (2013). https://doi.org/10.1038/nrneph.2013.83
Published:
Issue date:
DOI: https://doi.org/10.1038/nrneph.2013.83
